SAR-439459
- Generic Name
- SAR-439459
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 7EFI23P78R
- Background
SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody. Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
- Associated Conditions
- -
- Associated Therapies
- -
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT05231668
- Locations
- 🇺🇸
UCLA Health_Site Number: 8400006, Los Angeles, California, United States
🇺🇸Yale University - Site Number:8400007, New Haven, Connecticut, United States
🇺🇸Indiana University School of Medicine_Site Number: 8400002, Indianapolis, Indiana, United States
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath